Richard L Sidman


Affiliation: Harvard University
Country: USA


  1. Mandelin J, Cardo Vila M, Driessen W, Mathew P, Navone N, Lin S, et al. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci U S A. 2015;112:3776-81 pubmed publisher
    ..These previously unidentified ligand-receptor systems should be considered for targeted drug development against human metastatic androgen-independent prostate cancer. ..
  2. Sidman R, Li J, Lawrence M, Hu W, Musso G, Giordano R, et al. The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease. Sci Transl Med. 2015;7:309ra165 pubmed publisher
    ..This prototype drug candidate is a promising new dual receptor inhibitor of the VEGF ligand with potential for translation into safer, less-invasive applications to combat pathological angiogenesis in retinal disorders. ..
  3. Mintz P, Rietz A, Cardo Vila M, Ozawa M, Dondossola E, Do K, et al. Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer. Proc Natl Acad Sci U S A. 2015;112:2515-20 pubmed publisher
  4. Christianson D, Dobroff A, Proneth B, Zurita A, Salameh A, Dondossola E, et al. Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. Proc Natl Acad Sci U S A. 2015;112:2521-6 pubmed publisher
    ..Our results revealed that PPP2R1A is a new biomarker for melanoma metastasis and show, for the first time to our knowledge, an active interaction between the lymphatic vasculature and melanoma cells during tumor progression. ..
  5. Hosoya H, Dobroff A, Driessen W, Cristini V, Brinker L, Staquicini F, et al. Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release. Proc Natl Acad Sci U S A. 2016;113:1877-82 pubmed publisher
    ..These results are meaningful steps toward the design and initial translation of an enabling nanotechnology platform with potential for broad clinical applications. ..
  6. Dondossola E, Dobroff A, Marchiò S, Cardó Vila M, Hosoya H, Libutti S, et al. Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors. Proc Natl Acad Sci U S A. 2016;113:2223-8 pubmed publisher
    ..In a clinical context, this unique paradigm represents a personalized approach to be translated into applications potentially using patient-derived circulating tumor cells as self-targeted vectors for drug delivery. ..
  7. Smith T, Yuan Z, Cardó Vila M, Sánchez Claros C, Adem A, Cui M, et al. AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas. Proc Natl Acad Sci U S A. 2016;113:2466-71 pubmed publisher
  8. Ferrara F, Staquicini D, Driessen W, D Angelo S, Dobroff A, Barry M, et al. Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. Proc Natl Acad Sci U S A. 2016;113:12786-12791 pubmed publisher
    ..Our findings demonstrate the feasibility of GPR78-targeting, ligand-directed theranostics for translational applications in AVPC. ..
  9. Dobroff A, D Angelo S, Eckhardt B, Ferrara F, Staquicini D, Cardo Vila M, et al. Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proc Natl Acad Sci U S A. 2016;113:12780-12785 pubmed publisher
    ..g., invasive and/or metastatic) subtypes of breast cancer, based on the inducible cell-surface expression of the stress-response chaperone GRP78, and possibily other cell-surface receptors in human tumors. ..

More Information


  1. Nunes D, Dias Neto E, Cardó Vila M, Edwards J, Dobroff A, Giordano R, et al. Synchronous down-modulation of miR-17 family members is an early causative event in the retinal angiogenic switch. Proc Natl Acad Sci U S A. 2015;112:3770-5 pubmed publisher
  2. Tang F, Staquicini F, Teixeira A, Michaloski J, Namiyama G, Taniwaki N, et al. A ligand motif enables differential vascular targeting of endothelial junctions between brain and retina. Proc Natl Acad Sci U S A. 2019;: pubmed publisher
    ..Furthermore, the peptide allows for in vivo imaging, demonstrating that new tools for studying and imaging the brain are likely to emerge from this motif. ..
  3. Sardi S, Viel C, Clarke J, Treleaven C, Richards A, Park H, et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc Natl Acad Sci U S A. 2017;114:2699-2704 pubmed publisher
    ..Hence, inhibition of GCS represents a disease-modifying therapeutic strategy for GBA-related synucleinopathies and conceivably for certain forms of sporadic disease. ..
  4. Brammer D, Gillespie P, Tian M, Young D, Raveendran M, Williams L, et al. MLH1-rheMac hereditary nonpolyposis colorectal cancer syndrome in rhesus macaques. Proc Natl Acad Sci U S A. 2018;115:2806-2811 pubmed publisher
    ..The newly discovered hereditary nonpolyposis colorectal cancer syndrome in rhesus macaques, termed MLH1-rheMac, may serve as a model for development of novel approaches to diagnosis and therapy of Lynch syndrome in humans. ..
  5. Sidman R, Taksir T, Fidler J, Zhao M, Dodge J, Passini M, et al. Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice. J Neuropathol Exp Neurol. 2008;67:803-18 pubmed publisher
    ..A better understanding of the basis for clinical manifestations is needed to correlate CNS pathology with Pompe disease manifestations...